GeNeuro lists on Euronext Paris

Jesús Martin-Garcia, Chairman and CEO of GeNeuro, rings the opening bell, while the company celebrates its listing on Euronext Paris.

GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis and other diseases associated with human endogenous retroviruses (HERV). GeNeuro seeks to block a suspected source of the inflammatory and neurodegenerative components of the disease, rather than targeting the immune response of the body as do most current treatments.